Wear the standard
Collection 001
Heavyweight garments for the morning people. Cream, forest, navy. First release goes to the list.
Only what peer-reviewed science supports.
The rest, we name and refuse to sell.
Run more. Sleep more.
Sunlight before screens.
Cold water, warm people.
And when you supplement — only the good drugs.
We believe diet, exercise, and the right scientific supplementation can optimize any human. So we grade everything the way the literature does — meta-analyses over marketing, endpoints over biomarkers, effect sizes over anecdotes — and we only stock what clears the bar. No vibes. No "how it makes me feel." The effective list is short. That's the point.
Seventeen products. Every one carries its evidence grade, its honest effect size, and exactly who it's for — including where the science differs for women and men.
Longevity compounds that are biomarker-proven or trial-stage — endpoints pending. We show you what's proven, what isn't yet, and the exact trial we're waiting on. When the readouts land, this page changes first.
Every major longevity trial that could change this catalog, in plain language.
| Trial | What it tests | Status | If it hits |
|---|---|---|---|
| ER-100 · Phase 1 | Partial epigenetic reprogramming (OSK) in humans — optic neuropathies. The first human trial of the age-reversal thesis. | First patient dosed · Jun 2026 | The information theory of aging gets its first human data point. |
| ABLE · RCT | Calcium alpha-ketoglutarate vs placebo on biological age in middle-aged adults. | Recruiting / underway | Ca-AKG becomes the first supplement with RCT-backed bio-age evidence. |
| MIB-626 / MIB-725 | Pharmaceutical NAD+ boosters as drugs, with clinical endpoints (incl. heart failure). | Phase 1–2 · dosing 2025–26 | The NAD+ thesis finally gets endpoint-grade evidence, either way. |
| Mayo senolytic trials | Fisetin for frailty and bone health in older adults. | Reading out | Senolytics move from mouse story to human protocol. |
| TAME | Metformin against age-related disease onset in non-diabetics. | Still seeking full funding | The first drug formally tested against aging itself. |
| XPrize Healthspan | $101M competition incl. an oral reprogramming candidate (SL-100). | Announced Jun 2026 | A public benchmark for functional age reversal claims. |
Not here — and we'll tell you exactly why. The molecule that launched the longevity era turned out to activate its target only in the test tube (an assay artifact, shown by two independent pharma labs in 2010), failed to extend lifespan in the NIA's gold-standard mouse program, and was shelved by GSK after a $720M bet. We love the story — it's how science is supposed to work. But the evidence went the other way, so the product isn't on the shelf. That's the whole promise of this store.
Most of these aren't "unproven" — they were tested, and they failed. We keep the receipts so you don't pay for them.
No sex/goal picker. Tell us what you’re optimizing for. Saved stack is Carry cards only. Frontier can brief. Not a doctor.
Start the consultHeavyweight garments for the morning people. Cream, forest, navy. First release goes to the list.
Collection 001 and the first Good List drop go to the list before anyone else.
No spam. Just doses of what's real.
You're on the list. We'll write when it's time.